Moneycontrol PRO
you are here: HomeNewsBiocon

Biocon

Jump to
  • How will Coherus' Humira biosimilar launch at sharp discount play out for Biocon? June 05, 2023 05:34 PM IST

    How will Coherus' Humira biosimilar launch at sharp discount play out for Biocon?

    Nuvama believes Coherus' limited capacity is unlikely to bring a disruption in Humira biosimilar's market dynamics.

  • Biocon share price gains as USFDA issues 'no observations' on Bengaluru facility June 05, 2023 09:51 AM IST

    Biocon share price gains as USFDA issues 'no observations' on Bengaluru facility

    The share touched a 52-week high of Rs 344 and a 52-week low of Rs 191.60 on 10 June, 2022 and 21 March, 2023, respectively.

  • Hold Biocon; target of Rs 266: Sharekhan May 31, 2023 02:27 PM IST

    Hold Biocon; target of Rs 266: Sharekhan

    Sharekhan recommended Hold rating on Biocon with a target price of Rs 266 in its research report date May 29, 2023.

  • Indian pharma must ensure compliance with global standards: Kiran Mazumdar-Shaw May 29, 2023 02:51 PM IST

    Indian pharma must ensure compliance with global standards: Kiran Mazumdar-Shaw

    Slowing global economic conditions are expected to trigger greater utilisation of generic drugs and biosimilars because they offer lower-cost alternatives to expensive branded drugs, she said.

  • Neutral Biocon; target of Rs 260: Motilal Oswal May 28, 2023 02:50 PM IST

    Neutral Biocon; target of Rs 260: Motilal Oswal

    Motilal Oswal recommended Neutral rating on Biocon with a target price of Rs 260 in its research report dated May 24, 2023.

  • Gainers & Losers: 10 Stocks that moved the most on May 24 May 24, 2023 05:16 PM IST

    Gainers & Losers: 10 Stocks that moved the most on May 24

    The Sensex was down 208.01 points or 0.34 percent at 61,773.78, and the Nifty was down 62.60 points or 0.34 percent at 18,285.40. About 1,643 shares advanced, 1,727 shares declined, and 125 shares unchanged.

  • Biocon Consolidated March 2023 Net Sales at Rs 3,773.90 crore, up 56.67% Y-o-Y May 24, 2023 11:42 AM IST

    Biocon Consolidated March 2023 Net Sales at Rs 3,773.90 crore, up 56.67% Y-o-Y

  • Biocon Standalone March 2023 Net Sales at Rs 506.70 crore, down 2.12% Y-o-Y May 24, 2023 11:08 AM IST

    Biocon Standalone March 2023 Net Sales at Rs 506.70 crore, down 2.12% Y-o-Y

  • Biocon shares surge 8% on 31% growth in Q4 net profit May 24, 2023 10:29 AM IST

    Biocon shares surge 8% on 31% growth in Q4 net profit

    Biocon's net profit as well as revenue for the quarter topped the Street's estimates.

  • Market remains watchful but there is good news on ITC, NMDC and Biocon | Market Minutes May 24, 2023 08:42 AM IST

    Market remains watchful but there is good news on ITC, NMDC and Biocon | Market Minutes

    In this episode of Market Minutes, Asha Menon talks about global markets’ cautious waiting for talks in US to reach a resolution and why oil prices are inching up while gold is slipping. Also, Sanjay Manyal, Senior Research Analyst at ICICI Securities, shares why he believes the ITC rally has a longer run and which are the verticals he is optimistic about. Market Minutes is a morning podcast that puts the spotlight on hot stocks, keys data points and developing trends (with inputs from Shivam Shukla).

  • Short Call | New Crompton CEO’s job pangs, Biocon, Peter Lynch’s regrets not ‘sinning’ April 26, 2023 08:40 AM IST

    Short Call | New Crompton CEO’s job pangs, Biocon, Peter Lynch’s regrets not ‘sinning’

    Plenty of stock-specific activity, particularly in some of the railway names, but the sense one gets talking to market players is nobody is making serious money

  • Bernstein Research removes IEX short, adds RIL, Biocon, M&M to portfolio April 21, 2023 01:06 PM IST

    Bernstein Research removes IEX short, adds RIL, Biocon, M&M to portfolio

    Bernstein Research has added Reliance Industries Ltd, Biocon Ltd, and Mahindra and Mahindra Ltd to its portfolio and has eliminated its cash allocation and covered its short positions from IEX as it expects a market rebound in 2QCY23.

  • Improved sentiment, hopes of better sales fuel gains in pharma stocks; Divi's Lab spurts 8% April 12, 2023 12:29 PM IST

    Improved sentiment, hopes of better sales fuel gains in pharma stocks; Divi's Lab spurts 8%

    Multiple counters in the pharmaceutical space, including Divi's Laboratories, Cipla, Sun Pharmaceuticals, Lupin, and Natco Pharma also witnessed large deals on April 12.

  • Kotak retains 'reduce' rating on Biocon; lowers target price March 24, 2023 01:11 PM IST

    Kotak retains 'reduce' rating on Biocon; lowers target price

    Brokerage firm Kotak Institutional Equities has retained a "reduce" rating on Biocon Ltd (BIOS) and lowered its target price to Rs 210 from Rs 240 earlier.

  • Short Call | The PVR story, HNI frustration, Biocon bother, and the moral hazard March 22, 2023 08:37 AM IST

    Short Call | The PVR story, HNI frustration, Biocon bother, and the moral hazard

    FIIs are now 83 percent net short on index futures, but the massive short-covering that bulls are counting on, has turned out to be elusive so far

  • Ahan-I offloads 1.5% stake in Biocon for Rs 380 cr March 17, 2023 11:29 PM IST

    Ahan-I offloads 1.5% stake in Biocon for Rs 380 cr

    According to the bulk deal data available with NSE, Ahan-I Ltd offloaded 1,89,28,363 equity shares, amounting to a 1.57 per cent stake in the company.

  • Mutual funds added IT and new-age tech stocks in February, sold banks March 15, 2023 07:18 AM IST

    Mutual funds added IT and new-age tech stocks in February, sold banks

    Among IT names, shares of Tech Mahindra, Coforge, LTIMindtree and HCL Technologies were the top buys

  • Buy Biocon; target of Rs 266: Sharekhan February 27, 2023 01:28 PM IST

    Buy Biocon; target of Rs 266: Sharekhan

    Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 266 in its research report dated February 21, 2023.

  • Easing margin pressures, uptick in US sales saving grace for pharma firms in Q3 February 22, 2023 05:58 PM IST

    Easing margin pressures, uptick in US sales saving grace for pharma firms in Q3

    Despite moderation in margin pressure, a rise in input costs for some medications can derail pharma sector's recovery, say analysts

  • Pharma sector gets first tranche of payment under under PLI scheme February 22, 2023 06:38 AM IST

    Pharma sector gets first tranche of payment under under PLI scheme

    Dr Reddy's Laboratories Limited, Biocon Limited, Strides Pharma Science Limited and Premier Medical Corporation Private Limited have been granted the incentives in the first phase

  • Biocon Standalone December 2022 Net Sales at Rs 555.00 crore, up 17.34% Y-o-Y February 20, 2023 11:50 AM IST

    Biocon Standalone December 2022 Net Sales at Rs 555.00 crore, up 17.34% Y-o-Y

  • Biocon Consolidated December 2022 Net Sales at Rs 2,941.10 crore, up 35.27% Y-o-Y February 17, 2023 11:39 AM IST

    Biocon Consolidated December 2022 Net Sales at Rs 2,941.10 crore, up 35.27% Y-o-Y

  • Live: Kiran Mazumdar Shaw On Biocon Q3 Results, Viatris Deal & Drug Regulation In India February 16, 2023 11:51 AM IST

    Live: Kiran Mazumdar Shaw On Biocon Q3 Results, Viatris Deal & Drug Regulation In India

    'India will miss the boat if we don't have good regulatory capabilities to approve newer products', says Biocon Executive Chairperson Kiran Mazumdar Shaw on India's pharma industry. Shaw also speaks about the company's Q3 numbers, business strategy and the Viatris deal. Watch!

  • Biocon reports a consolidated net loss of Rs 42 crore in Q3. Here’s what analysts say February 16, 2023 11:44 AM IST

    Biocon reports a consolidated net loss of Rs 42 crore in Q3. Here’s what analysts say

    A one-time loss of Rs 271 crore during the quarter, mainly owing to professional fees paid for the acquisition of the global biosimilars business of American company Viatris, triggered the loss

  • Biocon aims to become the largest biosimilar company globally: Kiran Mazumdar-Shaw February 16, 2023 01:16 PM IST

    Biocon aims to become the largest biosimilar company globally: Kiran Mazumdar-Shaw

    Biocon Chairman sees biologics business hitting Rs 2,000 crore in the fourth quarter; says there's a need to build robust regulatory system to curb instances of adulteration of drugs by Indian pharma firms.